The FDA has granted accelerated approval to Tzield (teplizumab) to delay the decline in endogenous insulin production in children ages 8 to 17 years recently diagnosed with stage 3 Type 1 diabetes.
The approval makes Tzield the first disease-modifying therapy approved in the U.S. for patients recently diagnosed with stage 3 Type 1 diabetes, according to a June 13 news release from drugmaker Sanofi. The indication was supported by results from the Protect phase 3 study and data from a broader clinical development program involving more than 900 patients who received the therapy.
In the study, patients receiving Tzield experienced a slower decline in insulin production than those receiving a placebo. The FDA granted the indication under its accelerated approval pathway based on evidence of reduced C-peptide decline.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
